Evidence map›Paper›PMID 18492055›Full record

ArticleImmunology2008

CD66a (CEACAM1) expression by mouse natural killer cells.

Gaëtan Thirion, Ana Agusti Feliu, Jean-Paul Coutelier

Abstract read
In one paragraph

Article in Immunology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Gaëtan ThirionUnit of Experimental Medicine, Christian de Duve Institute, Université Catholique de Louvain, Brussels, Belgium.
Ana Agusti Feliu
Jean-Paul Coutelier

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD66a (CEACAM1), an adhesion molecule that has regulatory function on T lymphocytes, was found to be expressed on a minority of mouse natural killer (NK) cells, especially in the liver. CD66a expression on NK cells depended on their differentiation stage, with highest levels on immature CD49b(-)NK cells. Expression of CD66a on NK cells was strongly enhanced by in vitro activation with interleukin-12 (IL-12) and IL-18. However, in vivo NK cell stimulation by infection with lactate dehydrogenase-elevating virus did not lead to strong CD66a expression, even on activated interferon--gamma-producing NK cells. These results indicate that CD66a expression is differently regulated, depending on the NK cell activation pathway, which may lead to distinct regulatory mechanisms of the functional subpopulations of these cells.

Indexed as

AnimalsAntigens, CDAntigens, LyArterivirus InfectionsCell Adhesion MoleculesFemaleFlow CytometryIntegrin alpha2Interferon-gammaKiller Cells, NaturalLactate dehydrogenase-elevating virusLiverLymphocyte ActivationMiceMice, Inbred BALB CMice, Inbred C57BLAntigens, CDAntigens, LyCD66 antigensCell Adhesion MoleculesIntegrin alpha2Interferon-gammaKlrb1c protein, mouseNK Cell Lectin-Like Receptor Subfamily B

Identifiers

PMID18492055
PMCPMC2612550

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.